Donepezil Transdermal Patch Eutectic Matrix for Skin Permeation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current donepezil formulations, particularly oral and transdermal compositions, face challenges such as hepatic and digestive side effects, poor skin permeation rates, and difficulties in maintaining therapeutic efficacy over a long period due to low drug concentration and adhesive strength issues.
Innovation Solution
A transdermal composition with a drug-permeable double-layer system, comprising a backing layer, a drug-containing matrix layer with 15-55% donepezil, 25-70% EVA-based adhesive, and 5-20% pyrrolidone or C8-18 aliphatic derivative, and a polymer adhesive matrix layer with 60% or more acrylic adhesive, designed for improved skin permeation and prolonged adhesion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral donepezil composition is used, then therapeutic effect is achieved, but hepatic and digestive side effects occur
Solution Approach 1:
The patent uses the skin as an intermediary route for drug delivery, bypassing the hepatic first-pass metabolism and digestive tract. The transdermal patch delivers donepezil directly through the skin into systemic circulation, eliminating the harmful hepatic and digestive side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent extracts the donepezil drug from the oral administration route and transfers it to a transdermal delivery system. This extraction removes the drug from the problematic digestive and hepatic pathways while preserving its therapeutic action through alternative transdermal absorption.
2Object-affected harmful factors
If transdermal composition is used, then side effects are reduced, but skin permeation rate is poor
Solution Approach 1:
The patent changes the physical and chemical parameters of the drug delivery system by using a eutectic mixture of donepezil hydrochloride and magnesium chloride. This parameter change lowers the melting point and enhances the permeation properties of the drug, significantly improving skin permeation rate while maintaining the advantage of reduced side effects.
Solution Approach 2:
The patent creates a composite material system consisting of donepezil hydrochloride and magnesium chloride in a eutectic mixture. This composite material combines the therapeutic properties of donepezil with the permeation-enhancing properties of magnesium chloride, achieving both reduced side effects and improved skin permeation.
3Object-affected harmful factors
If low concentration of donepezil is used in transdermal patch, then skin irritation is reduced, but therapeutic efficacy cannot be maintained over long period
Solution Approach 1:
The patent utilizes the eutectic mixture parameter change to increase drug solubility and permeation efficiency. This allows for optimized drug loading in the transdermal patch that maintains therapeutic efficacy over extended periods while controlling skin irritation through the improved drug delivery characteristics of the eutectic system.
Solution Approach 2:
The patent ensures continuous therapeutic action by designing a transdermal patch with sustained release characteristics. The eutectic mixture enables continuous drug availability at the skin surface, maintaining therapeutic efficacy for extended periods (typically 3-5 days) while the controlled release profile prevents excessive local concentration that could cause irritation.
4Reliability
If high concentration of donepezil is used in transdermal patch, then therapeutic efficacy is improved, but adhesive strength decreases
Solution Approach 1:
The patent changes the physical state and solubility parameters of donepezil by forming a eutectic mixture with magnesium chloride. This parameter change allows for higher effective drug concentration in the transdermal matrix while maintaining matrix integrity and adhesive properties, as the eutectic system provides a stable, homogeneous structure that preserves adhesive strength.
Solution Approach 2:
The patent employs a composite material system where donepezil hydrochloride and magnesium chloride form a eutectic mixture integrated into the adhesive matrix. This composite structure allows high drug loading while the magnesium chloride component and eutectic formation maintain the physical integrity and adhesive characteristics of the patch, preventing the strength reduction that would normally occur with high drug concentrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves reduced skin irritation, enhanced skin permeation rates, and sustained therapeutic effects for an extended period, minimizing side effects and improving compliance for patients with dementia.
Implementation Method 1
5-20 wt % of at least one selected from the group consisting of a pyrrolidone derivative and a C8-18 aliphatic derivative
Implementation Method 2
25-70 wt % of an EVA-based adhesive
Implementation Method 3
a polymer adhesive matrix layer comprising, based on a total weight of the polymer adhesive matrix layer, 60 wt % or more of an acrylic adhesive
Data Source
AI summary
The present invention relates to a transdermal composition for dementia treatment containing donepezil as an active ingredient. The transdermal composition according to the present invention contains highly concentrated donepezil in a hydrophobic matrix, can continuously release the drug for a long time by having excellent long-term adhesion to the skin, and further exhibits consistently effective therapeutic effects over a long period of time by having a significantly improved skin penetration rate in comparison with conventional donepezil patches.